genprowebdirectory
GEN Edge
News
Insights
Trends for 2020
A-Lists
Topics
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
Magazine
Resources
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
Subscribe
Create a Free Account
Get GEN Edge
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Search
Advertising
Magazine Advertising
Website Banner Advertising
eNewsletter Advertising
Webinar Sponsorship
eBook Advertising
Email Nurture Campaigns
Ad Terms and Conditions
About GEN
Contact GEN
Create a Free Account
Get GEN Edge
Log In
GEN – Genetic Engineering and Biotechnology News
Mary Ann Liebert, Inc. Publishers
GEN Edge
Coronavirus
Rough Surf Ahead for California
Cancer
Alpine’s Gold Standard Approach to Drug Development
Biomarkers
Precision M&A: Invitae Eyes Growth in Personalized Cancer Tests, Services with…
Gene Therapy
Obsidian’s SWFT Response to COVID-19
Antibody Drug Conjugates
AbCellera’s CEO: Flattening the Curve of Technology Development
News
News
Protein Pathway May Help GvHD Lose Its Sting
Neuroscience
RNA Editing Repairs Rett Syndrome Mutation in Mice
OMICs
Rheumatoid Arthritis Flares Forewarned by Blood Levels of Newly Identified Cell…
CAR T-Cells
HER2 CAR T Therapy Dramatically Improves Child’s Refractory Cancer
CRISPR-Cas9
Base Editor Converts “Wanted” Cs, Spares “Bystander” Cs
Insights
All
Trends for 2020
Bioprocessing
Deeper Process Knowledge Bodes Well for Better Biopharmaceuticals
Bioprocessing
Making Biotherapeutics In Vivo Both an Opportunity and Challenge
Bioprocessing
Rentschler Biopharma Focuses on Reducing Timelines with Process Intensification
Coronavirus
Bacteriophages Could Be a Potential Game Changer in the Trajectory of…
A-Lists
July 2020 Vol. 40 No. 7
Top 10 Earners among Women Biopharma Executives
June 2020 Vol. 40 No. 6
In Praise of Lesser-Sung Life Sciences Clusters
Coronavirus
Blinking Red: 25 Missed Pandemic Warning Signs
Coronavirus
Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development
Coronavirus
Catching Up to Coronavirus: Top 60 Treatments in Development
Topics
All
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
OMICs
Rheumatoid Arthritis Flares Forewarned by Blood Levels of Newly Identified Cell…
CAR T-Cells
HER2 CAR T Therapy Dramatically Improves Child’s Refractory Cancer
CRISPR-Cas9
Base Editor Converts “Wanted” Cs, Spares “Bystander” Cs
Biobanking
Novel Glioblastoma Therapies May Lie in New Biobank
Magazine
July 2020 Vol. 40 No. 7
Rosalind Franklin the Scientist
July 2020 Vol. 40 No. 7
COVID-19 Research: Women Are Changing the Face of the Pandemic
July 2020 Vol. 40 No. 7
CRISPR Screening Explores New Dimensions
July 2020 Vol. 40 No. 7
Top 10 Earners among Women Biopharma Executives
Commentary
Clues to Healthier Aging in Cellular Senescence
Resources
All
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
Keynote Webinars
Life in the Time of Coronavirus
Upcoming Webinars
Uncover the True Identity of Your Particles with Comprehensive Particle Investigation
On Demand Webinars
GEN Live: COVID-19: Talking Next-Gen Diagnostics
Tutorial
Cultivation of Diverse and Rare Bacteria from Human Gut Microbiome
Subscribe
Create a Free Account
Get GEN Edge
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Home
Therapeutics
Enzyme Replacement Therapy
Enzyme Replacement Therapy
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Enzyme Replacement Therapy
Rubius Therapeutics Closes $120M Financing, Plans Trials Next Year
Enzyme Replacement Therapy
Alexion to Eliminate 7% of Workforce
Enzyme Replacement Therapy
Amicus Cuts Jobs, Overhauls GSK Collab, and Acquires Callidus
Enzyme Replacement Therapy
Lonza to Manufacture Heart Failure Enzyme Replacement Therapy
Enzyme Replacement Therapy
Genzyme Gets FDA, EMA Approvals for Production Plant in Waterford, Ireland
Enzyme Replacement Therapy
Protalix, Pfizer Report FDA Approval of Plant-Derived Gaucher Disease ERT Elelyso
Enzyme Replacement Therapy
EMA Green-Lights Shire’s Manufacturing Site in Lexington, MA, for Gaucher Therapy
Enzyme Replacement Therapy
Alexion Pays $610M to Buy Enobia for Hypophosphatasia ERT Candidate
Enzyme Replacement Therapy
Oxyrane Raises $26.5M to Take Lead Enzyme Replacement Therapy Through Phase...
Enzyme Replacement Therapy
Enobia Raises $40M to Further Develop Phase II-Stage ERT for Hypophosphatasia
Enzyme Replacement Therapy
Synageva Merges with Trimeris in All-Stock Deal
Enzyme Replacement Therapy
Halozyme and Intrexon to Develop Subcutaneous Recombinant Alpha 1-Antitrypsin Replacement Therapy
Enzyme Replacement Therapy
Synageva Raises $25M Through Private Placement with Existing Investors
Enzyme Replacement Therapy
Enobia Chooses Lonza for Commercial-Scale Manufacture of Its Enzyme-Replacement Therapy
Enzyme Replacement Therapy
GSK Pays Amicus $30M Up Front for Phase III Fabry Disease...
Load more
Scroll Up
Please wait while you are redirected to the right page...
We use cookies to give you a better experience on genengnews.com. By continuing to use our site, you are agreeing to the use of cookies as set in our
privacy policy.
Got it!
Edit with Live CSS
/* The alert message box */ .alert { padding: 20px; background-color: #ff9800; /* Red */ color: white; margin-bottom: 15px; } /* The close button */ .closebtn { margin-left: 15px; color: white; font-weight: bold; float: right; font-size: 22px; line-height: 20px; cursor: pointer; transition: 0.3s; } /* When moving the mouse over the close button */ .closebtn:hover { color: black; } .td_module_flex_2 .entry-title { font-size: 17px; line-height: 20px; }
![The new entity will be publicly traded and will focus on orphan drugs. [© Sergey Ilin - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/June13_2011_18890711_RubberManRedPiePiece_SynagevaTrimerisMerger2313447113-324x160.jpg "Synageva Merges with Trimeris in All-Stock Deal")
![Funds will be used to continue clinical development of lead LAL deficiency enzyme replacement therapy.[© Bobby4237 - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/UGENWebsitepicturesTopStoriesMarch2011March21_2011_Spreadof100dollarbills_SynagevaFinancing2005712466-324x160.jpg "Synageva Raises $25M Through Private Placement with Existing Investors")
![Pharmacological chaperone is designed to stabilize a-GAL A and restore its activity.[Sergey Ilin-Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/UGENWebsitepicturesTopStoriesOct2010Oct29_18890711_RubberManRedPiePiece_GSKtakesStakeinAmicusforFabryDisease5122732422-324x160.jpg "GSK Pays Amicus $30M Up Front for Phase III Fabry Disease Drug")
